Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leonel Vance

Interventional Pain Medicine Madison, MS Medical Doctor

NPI 1669507943 CMS profile 29648

129 Fountains Blvd, Ste 201, Madison, MS 39110

Open in the dashboard

General payments

$21,071

188 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leonel Vance of Madison, MS is reported in the CMS Open Payments database as having received $21,071 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,160 24
2024 General $236 11
2023 General $634 13
2022 General $862 21
2021 General $1,178 35
2020 General $724 28
2019 General $15,278 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leonel Vance
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Leonel Vance were reported at $2,160. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Leonel Vance Interventional Pain Medicine median Middle half National median
2019 $15,278 $684 $216–$2,079 $163
2020 $724 $382 $122–$1,109 $114
2021 $1,178 $552 $167–$1,554 $132
2022 $862 $605 $187–$1,924 $149
2023 $634 $671 $195–$1,915 $160
2024 $236 $684 $206–$1,837 $164
2025 $2,160 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $13,931 1 payment
  2. Abbott Laboratories $2,989 66 payments
  3. Spinal Simplicity, LLC $1,072 14 payments
  4. Medtronic, Inc. $683 18 payments
  5. Stryker Corporation $480 2 payments
  6. Collegium Pharmaceutical, Inc. $358 23 payments
  7. BIOTRONIK NRO, Inc. $333 5 payments
  8. SI-BONE, Inc. $252 2 payments
  9. Avanir Pharmaceuticals, Inc. $125 1 payment
  10. GRT US Holding, Inc. $110 2 payments
  11. Other $738 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $13,931 1 payment
  2. Food and Beverage $5,919 181 payments
  3. Travel and Lodging $1,179 4 payments
  4. Education $42 2 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $1,264 30 payments
  2. HA MINUTEMAN G3-R $1,072 14 payments
  3. Proclaim IPG $946 21 payments
  4. INTELLIS ADAPTIVESTIM $683 18 payments
  5. PROCLAIM $578 9 payments
  6. MILD DEVICE KIT $480 2 payments
  7. XTAMPZA $358 23 payments
  8. Prospera $333 5 payments
  9. NUEDEXTA $125 1 payment
  10. Qutenza $110 2 payments
  11. Other $1,116 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

116

Median for Interventional Pain Management: 1,220

Drug cost

$7,070

Median for Interventional Pain Management: $39,344

Branded share of claims

0%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methadone Hcl Generic 116 $7,070

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$320,992

Of which drugs: $129

Medicare patients

397

Average age 70

Services billed

4,842

261 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 38%
Diabetes 35%
Ischemic heart disease 27%
Osteoporosis 21%
Chronic kidney disease 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, propofol, 10 mg J2704 Office 59 1,554 $119
Injection, midazolam hydrochloride, per 1 mg J2250 Office 11 82 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record